❗Let's close the gap: We still need your help to raise $40,000 by April 1. Donate now

Valeant's story: a cautionary tale

Mar 21, 2016
The company's CEO stepped down on Monday
Howard Schiller, then interim CEO of Valeant Pharmaceuticals International, Inc., listens during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC. 
BRENDAN SMIALOWSKI/AFP/Getty Images

FDA takes step to improve generic drug competition

Mar 15, 2016
We'd pay a lot more if it wasn’t for generics, which amount to as much as 85% of what we take.
Joe Raedle/Getty Images

Valeant swears off aggressive drug pricing strategy

Mar 15, 2016
Valeant and a handful other firms may ditch a model that's come under fire.
 Valeant and a handful other firms  may ditch a model that's come under fire.
Image via Life Science Association of Manitoba/YouTube

Bad packaging means $3b in drugs will be wasted this year

Mar 1, 2016
A new report suggests drug makers are profiting from the waste.
A new report suggests drug makers are profiting from the waste.
Peter Macdiarmid/Getty Images

Why rare-disease treatments can be big business

Jan 11, 2016
Combined, Shire and Baxalta expect 65 percent of total revenue to come from rare disease treatments.

Drug company's subsidies to patients under review

Oct 15, 2015
Assistance programs are also marketing tools that can raise overall costs.